Market Overview - The beverage and dairy sector experienced a slight decline of 0.01% on January 20, with Junyao Health leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the beverage and dairy sector included: - Huanlejia (300997) with a closing price of 26.93, up 3.10% and a trading volume of 229,100 shares, totaling 616 million yuan [1] - Yangyuan Beverage (603156) closed at 34.45, up 1.62% with a trading volume of 116,300 shares, totaling 402 million yuan [1] - Weiwei Co. (600300) closed at 3.71, up 1.37% with a trading volume of 671,200 shares, totaling 248 million yuan [1] - Conversely, Junyao Health (605388) saw a decline of 2.57%, closing at 7.20 with a trading volume of 147,800 shares, totaling 106 million yuan [2] - Other notable decliners included: - Bei Yin Mei (002570) down 2.46% to 6.34 with a trading volume of 679,500 shares, totaling 432 million yuan [2] - Xibu Muye (300106) down 2.38% to 11.09 with a trading volume of 105,800 shares, totaling 118 million yuan [2] Capital Flow - The beverage and dairy sector saw a net outflow of 70.03 million yuan from institutional investors, while retail investors contributed a net inflow of 104 million yuan [2] - The capital flow for specific stocks indicated: - Yili Group (600887) had a net inflow of 91.01 million yuan from institutional investors, while retail investors experienced a net outflow of 61.14 million yuan [3] - Huanlejia (300997) had a net inflow of 60.50 million yuan from institutional investors, but a significant net outflow of 79.94 million yuan from retail investors [3] - Knight Dairy (920786) had a net inflow of 11.97 million yuan from institutional investors, with minimal impact from retail investors [3]

Core Viewpoint - Junyao Health (605388.SH) anticipates a significant decline in net profit for 2025, projecting a loss of between 216 million yuan and 144 million yuan due to pressures on its main business, high expenses, and planned asset impairment provisions [1] Financial Performance - The company expects a net profit attributable to shareholders of -216 million to -144 million yuan for 2025, a decrease of 115 million to 187 million yuan compared to the previous year, representing a year-on-year decline of 395.14% to 642.71% [1] - The projected non-recurring net profit is estimated to be -233 million to -155 million yuan, a reduction of 97.04 million to 175 million yuan year-on-year, equating to a decline of 167.33% to 301.00% [1] Reasons for Performance Decline - The decline in performance is attributed to several factors, including a challenging consumer environment leading to reduced market share in the dairy beverage sector and decreased revenue from traditional ambient yogurt business [1] - Increased sales and marketing expenses due to efforts to expand e-commerce, new retail, and chain channels have significantly raised costs compared to the previous year [1] - The company has also increased its R&D investment, contributing to higher expenses [1] Asset Impairment Provisions - Junyao Health plans to make multiple asset impairment provisions based on prudence, including: - Inventory impairment due to declining prices and extended liquidation periods, expected to impact profits by 30 million to 50 million yuan [2] - Credit impairment on receivables due to increased credit risk and decreased collateral value, anticipated to affect profits by 50 million to 90 million yuan [2] - Goodwill impairment related to certain subsidiaries, expected to impact profits by 15 million to 45 million yuan [2] - The total potential impairment could reach up to 185 million yuan, representing a significant source of non-operating losses [2] Business Challenges - Junyao Health is facing multiple challenges, including sluggish growth in its main business and profit pressures during its transformation phase [2] - The company is focusing on its probiotic business as a second growth curve, achieving substantial progress in strain research, but new business initiatives are still in the investment phase and have not yet contributed positively to overall financial performance [2]

Group 1 - The core announcement is regarding the share pledge and release by the controlling shareholder of Junyao Health, indicating a significant movement in the company's equity structure [1] - Junyao Health received a notice from its controlling shareholder, Shanghai Junyao (Group) Co., Ltd., about the release of 17,000,000 shares from pledge and the pledge of an equal number of shares [1] - This transaction reflects the ongoing financial management strategies of the controlling shareholder, which may impact the company's liquidity and investor perception [1]

Core Viewpoint - Junyao Health (605388) is expected to report a net loss of approximately 144 million to 216 million yuan for the year 2025, representing a significant decrease of about 115 million to 187 million yuan compared to the previous year, with a year-on-year decline of 395.14% to 642.71% [1] Group 1 - The primary reason for the performance change is the ongoing pressure on the consumption environment, which has led to a reduction in market share for dairy beverages and weak demand from downstream customers [1] - Revenue from the company's traditional ambient yogurt business has decreased compared to the same period last year, contributing to the decline in profit [1] Group 2 - The company is focusing on optimizing its revenue structure while actively expanding e-commerce channels, new retail channels, and chain KA channels [1] - This expansion has resulted in a significant increase in upfront sales and marketing expenses compared to the same period last year [1] Group 3 - The company has increased its investment in research and development, leading to a corresponding rise in R&D expenses [1]

Group 1 - The controlling shareholder of Junyao Health, Shanghai Junyao (Group) Co., Ltd., holds approximately 197 million shares, accounting for 32.75% of the total share capital of the company [1] - After the partial release of share pledges, Junyao Group has pledged a total of about 151 million shares, which represents 76.69% of its held shares and 25.11% of the company's total share capital [1] - The controlling shareholder, actual controller, and their concerted actors collectively hold about 404 million shares, which is 67.25% of the total share capital [1] Group 2 - The cumulative number of pledged shares by the controlling shareholder, actual controller, and their concerted actors (including this time) is approximately 282 million shares, accounting for 69.89% of their total holdings and 47% of the company's total share capital [1]

Core Viewpoint - Junyao Health expects a significant decline in net profit for the year 2025, projecting a loss between approximately 216 million yuan and 144 million yuan, which represents a year-on-year decrease of about 115 million yuan to 187 million yuan, equating to a decline of 395.14% to 642.71% compared to the previous year [1] Group 1: Financial Performance - The projected net profit for 2025 is expected to be between -216 million yuan and -144 million yuan [1] - This represents a decrease of approximately 115 million yuan to 187 million yuan compared to the same period last year [1] - The year-on-year decline is estimated to be between 395.14% and 642.71% [1] Group 2: Business Challenges - The decline in performance is primarily attributed to a challenging consumer environment, which has led to a reduction in market share for dairy beverages [1] - There is a noted lack of demand from downstream customers, resulting in decreased revenue from the company's traditional ambient yogurt business compared to the same period last year [1] Group 3: Strategic Initiatives - The company is focusing on optimizing its revenue structure and actively expanding e-commerce channels, new retail channels, and chain KA channels [1] - This strategic shift has resulted in a significant increase in upfront sales and marketing expenses compared to the previous year [1] - Additionally, the company has increased its investment in research and development, leading to a corresponding rise in R&D expenses [1]

Core Viewpoint - Junyao Health (605388.SH) expects a significant decline in net profit for the year 2025, projecting a loss between 216 million to 144 million yuan, representing a year-on-year decrease of 395.14% to 642.71% [1] Financial Projections - The company anticipates a net profit attributable to shareholders of the listed company for 2025 to be between -216 million to -144 million yuan, indicating a substantial year-on-year decline [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between -233 million to -155 million yuan, reflecting a year-on-year decrease of 167.33% to 301.00% [1]

关于控股股东部分股份解除质押 及部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 证券代码：605388 证券简称：均瑶健康 公告编号：2026-002 湖北均瑶大健康饮品股份有限公司 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）控股股东上海均 瑶（集团）有限公司（以下简称"均瑶集团"）持有公司股份总数为 196,632,002 股，占公司总股本的 32.75%。本次部分股份解除质押及质押后，均瑶集团累计 质押公司股份 150,800,000 股，占其所持公司股份总数的 76.69%，占公司总股本 的 25.11%。 ● 公司控股股东、实际控制人及其一致行动人持有公司股份 403,853,404 股， 占公司总股本的 67.25%。控股股东、实际控制人及其一致行动人累计质押股份 数量（含本次）合计 282,244,673 股，占其持股数量比例的 69.89%，占公司总股 本的 47.00%。 一、本次控股股东股份解除质押基本情况 公司于 2026 年 1 月 16 日收到公司控股股东 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2026-003 湖北均瑶大健康饮品股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1.经财务部门初步测算，预计 2025 年年度实现归属于上市公司股东的净利 润为-21,625.04 万元到-14,416.69 万元，与上年同期（法定披露数据）相比， 将减少 11,505.05 万元到 18,713.40 万元，同比减少 395.14%到 642.71%。 2.预计 2025 年年度实现归属于上市公司股东的扣除非经常性损益的净利润 为-23,257.02 万元到-15,504.68 万元，与上年同期（法定披露数据）相比，将 减少 9,704.89 万元到 17,457.23 万元，同比减少 167.33%到 301.00%。 重要内容提示： ● 业绩预告的具体适用情形：净利润为负值。 ● 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）预计 2025 年年 度实现归属于上市公司股东的净利润为-21,625.04 万元到-14,41 ...

Core Viewpoint - Junyao Health expects a significant decline in net profit for the fiscal year 2025, projecting a loss between 216.25 million yuan and 144.17 million yuan, representing a year-on-year decrease of 395.14% to 642.71% [1] Financial Performance - The company anticipates a non-recurring net profit loss ranging from 232.57 million yuan to 155.05 million yuan, reflecting a year-on-year reduction of 167.33% to 301.00% [1] - The expected decline in performance is attributed to a challenging consumer environment leading to decreased revenue from traditional business operations, increased expenses, and impairments related to inventory, receivables, and goodwill [1]